2021 Global Glaucoma Market Pipeline Focus Report-Novartis’ leading industry sponsor, with the highest total number of clinical trials, followed by AbbVie

Dublin, June 10, 2021 (Global News Agency) – “Market Focus: Glaucoma” Report has been added to ResearchAndMarkets.com provide.

This market focus report covers the glaucoma market, including major listed and pipeline drugs, clinical trials, upcoming and regulatory events, likelihood of success, recent events and analyst opinions, 10-year disease prevalence forecasts, licensing and acquisition transactions , As well as presenting drug-specific revenue forecasts.

Key points

• The publisher estimates that in 2019, there will be 99.7 million glaucoma epidemics among adults 40 years of age and older worldwide, and predicts that this number will increase to 119.4 million cases by 2028.
• It is estimated that Africa has the highest prevalence (4.79%), while Europe and Oceania have the lowest prevalence (2.93% and 2.97%, respectively).
• Most approved drugs in the glaucoma field target beta adrenergic receptors or prostaglandin F receptors. Almost all of these approved drugs are administered via topical routes, and the rest are intraocular/subretinal/subconjunctival or oral formulations.
• In the active clinical development of glaucoma, the highest proportion of industry-sponsored drugs is in phase II, and only one drug is in the NDA/BLA phase.
• Although a few mid- to late-stage drugs in the field of glaucoma are exploring new targets, the established target prostaglandin F receptor continues to lead clinical development. The most common drugs in the development of glaucoma are administered via intraocular/subretinal/subconjunctival routes.
• The high-impact events of glaucoma drugs include the top-line phase II test results of GAL-101, the top-line phase III test results of NCX 470, and the expected PDUFA date of DE-117.
• The overall probability of approving stage I glaucoma/ocular hypertension (ophthalmology) assets is 4.9%, and the average probability of drug progression from stage III is 57.1%. It takes an average of 8.8 years for the drug from the first stage to approval, while it takes 8.9 years for the entire ophthalmology field.
• The distribution of phase I-IV clinical trials indicates that most glaucoma trials are in the late stages of development, with 59% of trials in phase III-IV and 41% of trials in phase I-II.
• The United States is a leader in the number of global glaucoma clinical trials. Germany leads the major European markets, while Japan tops the list in Asia.
• Clinical trial activities in the field of glaucoma are dominated by completed trials. Novartis has completed the largest number of glaucoma clinical trials, with 156 trials.
• So far, Novartis is the leading industry sponsor in the total number of glaucoma clinical trials, followed by AbbVie

Key topics covered:

Overview

Key points

Disease background

treatment

• Eye drops
• Oral drugs
• Intraocular implants

Epidemiology

Listed drugs

Pipeline drug

Recent events and analyst opinions

• AKB-9778 for glaucoma (December 11, 2020)
• Nyxol for glaucoma treatment (November 7, 2019)
• NCX 470 for glaucoma (October 2, 2019)

Important upcoming events

Major regulatory events

• Phesgo and Roclanda are the new winners of EMA
• Allergan’s ophthalmic implant technology is approved by Durysta

Probability of success

Licensing and asset acquisition transactions

• Upjohn will spin off three companies in Australia to complete Viatris

Income opportunity

Clinical trial status

• Sponsor status
• Phased Sponsor

bibliography

appendix

Companies mentioned

• Allergan
• Astellas
• Merck
• Novartis
• Q Biomedicine
• towering

For more information about this report, please visit https://www.researchandmarkets.com/r/jdtmt8

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900